GLP-1 Squared claims fact-checked: what the science says

What did @therealdrleemd actually say?

The creator claims there is a combination product called "GLP-1 Squared" that pairs semaglutide and tirzepatide at lower doses. They say it is a "luxury designer version" used by wealthy people, that it produces fewer side effects than either drug alone, and they personally experienced less nausea and better appetite control on it. The video ends with a prompt to DM for pricing.

To be direct: this video is structured as a sales pitch, not patient education. The framing of a "rich people's secret" is a marketing device. The credential drop ("I'm Dr. Lee, TikTok's weight loss doc") is meant to lend authority to what is ultimately a product promotion. That context matters when evaluating every claim that follows.

Does the science back this up?

There is no published clinical evidence supporting the combination of semaglutide and tirzepatide as a superior or safer approach. Tirzepatide already acts on both GIP and GLP-1 receptors, which makes stacking a separate GLP-1 agonist on top of it pharmacologically redundant at best and unstudied at worst.

The claim that lower doses of each drug produce fewer side effects has some logic behind it. Dose-dependent nausea is well-documented with GLP-1 agonists. Davies et al. (2021, The Lancet) showed that semaglutide's gastrointestinal side effects are strongly tied to dose escalation. But that does not validate combining two agents. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) studied tirzepatide alone and found meaningful side effect reduction at lower doses without adding a second drug. If reduced side effects are the goal, titrating one medication more carefully is the evidence-based path.

There are no peer-reviewed trials on a product called "GLP-1 Squared." The name itself appears to be proprietary marketing language, not a recognized clinical formulation.

What did they get wrong (or right)?

Wrong: The implicit claim that this combination is proven safer or more effective. No head-to-head trial compares this stack to tirzepatide alone. Anecdote from the prescribing physician is not data.

Wrong: Describing it as "far less side effects" without evidence. One person's n=1 experience after a single injection is not a safety profile.

Wrong: Calling it the "luxury designer version of tirzepatide." This is compounded semaglutide plus tirzepatide, almost certainly from a 503A or 503B compounding pharmacy. Compounded drugs are not FDA-approved and are not equivalent to brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. The FDA has explicitly warned consumers about compounded semaglutide products (FDA Drug Safety Communication, 2023).

Partially right: Access to GLP-1 medications is genuinely limited by cost, and compounding pharmacies have expanded access for some patients. That is a real issue worth discussing. But the solution here is being sold, not prescribed thoughtfully.

What should you actually know?

Combining two GLP-1 pathway drugs is not standard of care. If you are interested in GLP-1 therapy, the starting point is a licensed clinician who reviews your full medical history, not a DM in response to a TikTok video. Compounded versions of semaglutide and tirzepatide exist in a legally complex space. The FDA removed semaglutide from its drug shortage list in 2024, which affects whether compounding these medications is even legal depending on your state and pharmacy.

The "lower dose equals fewer side effects" argument applies to monotherapy. It does not automatically extend to untested combinations. Drug interactions, receptor saturation, and cardiovascular effects of stacked GLP-1 agonists have not been studied in controlled trials. Before anyone considers an off-label combination like this, a conversation with an endocrinologist or obesity medicine specialist, not a social media physician, is the appropriate step.